EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Fluorescent Assay and Imidazole-Containing Inhibitors by Targeting SARS-CoV-2 Nsp13 Helicase

Chuang Zhang, Junhui Yu, Mingzhenlong Deng, Qingqing Zhang, Fei Jin, Lei Chen, Yan Li, Bin He

Molecules · 2024

DOI: 10.3390/molecules29102301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Chuang Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Med…. Hauptthemen laut MEDLINE: Antiviral Agents, Imidazoles, SARS-CoV-2, Viral Nonstructural Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GUIZHOU SCIENCE AND TECHNOLOGY DEPARTMENT OF CHINA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nsp13, a non-structural protein belonging to the coronavirus family 1B (SF1B) helicase, exhibits 5′–3′ polarity-dependent DNA or RNA unwinding using NTPs. Crucially, it serves as a key component of the viral replication–transcription complex (RTC), playing an indispensable role in the coronavirus life cycle and thereby making it a promising target for broad-spectrum antiviral therapies. The imidazole scaffold, known for its antiviral potential, has been proposed as a potential scaffold. In this study, a fluorescence-based assay was designed by labeling dsDNA substrates with a commercial fluorophore and monitoring signal changes upon Nsp13 helicase activity. Optimization and high-throughput screening validated the feasibility of this approach. In accordance with the structural characteristics of ADP, we employed a structural-based design strategy to synthesize three classes of imidazole-based compounds through substitution reaction. Through in vitro activity research, pharmacokinetic parameter analysis, and molecular docking simulation, we identified compounds A16 (IC50 = 1.25 μM) and B3 (IC50 = 0.98 μM) as potential lead antiviral compounds for further targeted drug research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsImidazolesSARS-CoV-2Viral Nonstructural ProteinsEnzyme AssaysHumansCOVID-19 Drug TreatmentFluorescent DyesMethyltransferasesMolecular Docking SimulationRNA Helicases

Stichwörter der Autor:innen

Nsp13activity assaycoronary virusimidazole derivativesinhibitor

Substanzen

Antiviral AgentsFluorescent DyesimidazoleImidazolesMethyltransferasesNsp13 protein, SARS-CoVRNA HelicasesViral Nonstructural Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laborato…
  • School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China.

Förderung

  • GUIZHOU SCIENCE AND TECHNOLOGY DEPARTMENT OF CHINA

Zitieren

APA

Zhang, C., Yu, J., Deng, M., Zhang, Q., Jin, F., Chen, L., Li, Y., & He, B. (2024). Development of a Fluorescent Assay and Imidazole-Containing Inhibitors by Targeting SARS-CoV-2 Nsp13 Helicase. Molecules. https://doi.org/10.3390/molecules29102301

Vancouver

Zhang C, Yu J, Deng M, Zhang Q, Jin F, Chen L, et al. Development of a Fluorescent Assay and Imidazole-Containing Inhibitors by Targeting SARS-CoV-2 Nsp13 Helicase. Molecules. 2024. doi:10.3390/molecules29102301

BibTeX
@article{Zhang2024,
  author = {Zhang, Chuang and Yu, Junhui and Deng, Mingzhenlong and Zhang, Qingqing and Jin, Fei and Chen, Lei and Li, Yan and He, Bin},
  title = {Development of a Fluorescent Assay and Imidazole-Containing Inhibitors by Targeting SARS-CoV-2 Nsp13 Helicase},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29102301}
}
Kostenlos starten →